US biotechnology firm Novavax on Monday announced that its Covid-19 vaccine demonstrated over 93 per cent efficacy against the predominantly circulating virus variants of concern and variants of interest and offered 100 per cent protection against moderate and severe disease.
The vaccine, which Serum Institute of India (SII) will produce in collaboration with Novavax for supplies at home and the world, has shown 90.4 per cent efficacy overall in late stage clinical trials and 91 per cent efficacy in high-risk populations. The development augurs well for India, which will procure 20 crore doses of Covovax (SII to produce and market Novavax vaccine by this name), a recombinant nanoparticle protein-based jab.